May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
VerisomeTM, a Novel injectable, Sustained Release, Biodegradable, Intraocular Drug Delivery System and Triamcinolone Acetonide
Author Affiliations & Notes
  • M. Hu
    Icon Bioscience, Inc., Sunnyvale, California
  • G. Huang
    Icon Bioscience, Inc., Sunnyvale, California
  • F. Karasina
    Icon Bioscience, Inc., Sunnyvale, California
  • V. G. Wong
    Icon Bioscience, Inc., Sunnyvale, California
  • Footnotes
    Commercial Relationships  M. Hu, Icon Bioscience, Inc., E; G. Huang, Icon Bioscience, Inc., E; F. Karasina, Icon Bioscience, Inc., E; V.G. Wong, Icon Bioscience, Inc., E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5627. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Hu, G. Huang, F. Karasina, V. G. Wong; VerisomeTM, a Novel injectable, Sustained Release, Biodegradable, Intraocular Drug Delivery System and Triamcinolone Acetonide. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5627. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : An injectable, sustained release, biodegradable drug delivery system is needed to optimally treat a wide variety of ophthalmic diseases. Many non-biodegradable triamcinolone acetonide (TA) implants which require sutures or surgical procedures have been reported. The authors evaluated the feasibility of VerisomeTM for the sustained release of TA.

Methods: : Two (2) VerisomeTM formulations containing triamcinolone acetonide (TA) 6.9 mg and 13.8 mg were injected into two groups of NZW rabbit vitreous, and drug levels were measured over a period of one (1) year. Drug toxicity was assessed over this same time period by ophthalmic examination and histologic examination.

Results: : The group injected with 6.9 mg of TA demonstrated sustained levels of TA in the vitreous for up to 6 months. The mean TA vitreous level was 1.5 µg/mL. Similarly, the group initially injected with 13.8 mg TA showed sustained levels of TA in the vitreous for up to one (1) year. The mean TA vitreous level was 1.1 µg/mL. There was no evidence of toxicity as determined by clinical examination and histologic examination.

Conclusions: : VerisomeTM is an injectable, biodegradable and effective delivery system for sustained intraocular administration of triamcinolone acetonide. The system appears well tolerated in the rabbit eye.

Keywords: vitreous • edema • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×